| Today’s Big NewsJan 25, 2024 |
|
This whitepaper reveals how to strategically scale processes, offering developers flexibility from 1,000L to an industry-leading 5,000L in a single-use bioreactor. Meticulous optimization ensures high-quality drug products, while expert-led parameter fine-tuning guarantees consistent growth across scales. Explore how suspension cells lead the way, providing a robust and adaptable manufacturing platform for gene therapy breakthroughs.
|
|
| By Gabrielle Masson Bristol Myers Squibb is proving its worth as an M&A competitor, coming out on top not once but twice in terms of fresh acquisitions. Most recently, the pharma’s $4.1 billion bid for radiopharmaceuticals biotech RayzeBio was enough to beat out two other companies that also put down offers. |
|
|
|
By Angus Liu Three months after launching an investigation into the risk of secondary T-cell cancers after treatment with a CAR-T medicine, the FDA has shared more information on the cases that it has seen. But questions remained unanswered. |
By Gabrielle Masson Saudi Arabia has launched a national biotech strategy in an effort to become an international biotech hub within the next 16 years. |
By Andrea Park The single-port system, dubbed da Vinci SP, has racked up clearances in the U.S. in recent years allowing it to be used in urology and transoral otolaryngology procedures. The newly bestowed CE mark allows European surgeons to use the SP platform in an even wider range of surgeries. |
By Angus Liu In a similar pattern as Novartis' radiotherapy Pluvicto, Exelixis now has positive prostate cancer data for a combination of Cabometyx and Roche's Tecentriq, and yet the drug developer can't immediately file for an FDA approval. |
By Andrea Park Abbott equated the height and width of the Liberta RC device to that of a smartwatch face and suggested that the implant could be placed in a spoonful of water “with room to spare.” |
By James Waldron In a move that will be seized on as a sign that the IPO window is reopening in 2023, CG Oncology has not only become the first biotech to go public this year but overshot its own estimates. |
By Kevin Dunleavy Two months ago, in presenting quarterly earnings, CEO Barry Greene said Sage Therapeutics was on its way to becoming a “leaner and stronger company.” Part of that mission will come to fruition later this year with a move of its headquarters in Cambridge, Massachusetts. Sage will shift from its 103,000-square-foot headquarters to a 30,567-square-foot office three blocks away, the company said in a regulatory filing. |
By Max Bayer Third Rock is fortifying its ranks, hiring three new venture partners and promoting two others at the firm. Among the new hires is Karuna Therapeutics founder Steve Paul. |
By Fraiser Kansteiner,Eric Sagonowsky,Angus Liu,Kevin Dunleavy,Zoey Becker In this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including expansions into key geographies and new indications. Some of these updates may not meet the bar for standalone stories, but we think they are still worth mentioning. |
Fierce podcastsDon’t miss an episode |
| At Fierce Pharma, the arrival of a new year is synonymous with the release of our annual special report on drug approvals. This week on “The Top Line,” Fierce Pharma’s Eric Sagonowsky and Kevin Dunleavy, both instrumental in creating the special report, are breaking down the numbers and sharing key insights into the landscape of drug approvals in 2023. |
|
|---|
|
|
|
This white paper explains how Resilience utilizes a Stage-Gate approach to technology transfer and biomanufacturing. Built on proven methods used across industries, the Stage-Gate approach mitigates risk while shortening cycle times throughout the project lifecycle. Download now.
|
|
| WhitepaperThe road to digital health innovation is exciting but complex and requires thoughtful navigation; this whitepaper serves as your guide through this process. Sponsored by: S3 Connected Health |
| Whitepaper Discover how to effectively classify highly potent APIs and the steps required to develop containment protocols and manufacturing processes that are both safe and efficient. Sponsored by: Catalent |
| eBook This e-book explores 7 factors that are critical to the success of emerging biopharma companies, whether they plan to out-license, partner, or launch & commercialize products. It’s an essential resource for emerging companies with products in all stages of development.
Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
